R1	Has_qualifier Arg1:T5 Arg2:T6	
*	OR T5 T7
R2	AND Arg1:T4 Arg2:T5	
R3	Has_qualifier Arg1:T9 Arg2:T10	
*	OR T12 T11
R4	AND Arg1:T9 Arg2:T12	
R5	Has_value Arg1:T23 Arg2:T26	
R6	Has_value Arg1:T24 Arg2:T26	
R7	Has_value Arg1:T25 Arg2:T26	
R8	Has_value Arg1:T27 Arg2:T28	
R9	Has_value Arg1:T29 Arg2:T30	
R10	AND Arg1:T27 Arg2:T29	
R11	AND Arg1:T29 Arg2:T32	
R12	Has_value Arg1:T36 Arg2:T37	
R13	Has_value Arg1:T34 Arg2:T35	
R14	Has_value Arg1:T38 Arg2:T39	
R15	AND Arg1:T33 Arg2:T34	
R16	AND Arg1:T33 Arg2:T38	
*	OR T44 T45
R17	AND Arg1:T43 Arg2:T44	
*	OR T46 T47
R18	Has_index Arg1:T51 Arg2:T52	
R19	Has_temporal Arg1:T50 Arg2:T51	
R20	Has_temporal Arg1:T49 Arg2:T51	
*	OR T49 T50
R21	Has_qualifier Arg1:T55 Arg2:T56	
R22	Has_temporal Arg1:T54 Arg2:T53	
R23	AND Arg1:T54 Arg2:T55	
R24	Has_value Arg1:T62 Arg2:T63	
R25	AND Arg1:T61 Arg2:T62	
*	OR T57 T59 T58 T60 T61
R27	Has_qualifier Arg1:T66 Arg2:T67	
R28	Has_index Arg1:T68 Arg2:T69	
R29	AND Arg1:T65 Arg2:T66	
R30	Has_temporal Arg1:T65 Arg2:T68	
R32	Has_temporal Arg1:T71 Arg2:T73	
R33	Has_multiplier Arg1:T74 Arg2:T77	
R34	Has_multiplier Arg1:T75 Arg2:T76	
R35	Has_temporal Arg1:T74 Arg2:T80	
R36	AND Arg1:T78 Arg2:T74	
R37	Subsumes Arg1:T77 Arg2:T75	
R38	Has_multiplier Arg1:T84 Arg2:T85	
R39	Has_temporal Arg1:T83 Arg2:T82	
R40	Subsumes Arg1:T83 Arg2:T84	
R41	AND Arg1:T89 Arg2:T87	
R42	AND Arg1:T90 Arg2:T88	
R43	Subsumes Arg1:T93 Arg2:T94	
*	OR T93 T95
R44	AND Arg1:T92 Arg2:T93	
R45	Subsumes Arg1:T105 Arg2:T106	
R46	Subsumes Arg1:T101 Arg2:T102	
*	OR T101 T105
*	OR T97 T100
R47	Has_index Arg1:T97 Arg2:T98	
R48	AND Arg1:T97 Arg2:T101	
R49	Has_index Arg1:T117 Arg2:T118	
R50	Has_temporal Arg1:T116 Arg2:T117	
R51	AND Arg1:T116 Arg2:T115	
R52	Has_temporal Arg1:T112 Arg2:T113	
R53	Has_index Arg1:T113 Arg2:T114	
*	OR T112 T116
*	OR T124 T125
*	OR T123 T122
R54	Subsumes Arg1:T123 Arg2:T124	
R55	Subsumes Arg1:T130 Arg2:T131	
R56	Has_qualifier Arg1:T132 Arg2:T133	
R57	Subsumes Arg1:T128 Arg2:T130	
R58	Subsumes Arg1:T134 Arg2:T135	
R59	Has_qualifier Arg1:T136 Arg2:T138	
R60	Subsumes Arg1:T136 Arg2:T137	
R61	AND Arg1:T16 Arg2:T17	
*	OR T128 T132
R31	AND Arg1:T71 Arg2:T72	
R62	Has_negation Arg1:T72 Arg2:T19	
R26	Has_negation Arg1:T57 Arg2:T140	
R63	AND Arg1:T54 Arg2:T57	
R64	Has_negation Arg1:T65 Arg2:T70	
R65	AND Arg1:T33 Arg2:T36	
R66	Subsumes Arg1:T105 Arg2:T107	
R67	Subsumes Arg1:T101 Arg2:T103	
R68	Subsumes Arg1:T101 Arg2:T104	
T1	Context_Error 0 155	Prior treatment toxicities have not resolved to < Grade 2 according to NCI CTCAE Version 4.0 (except clinically insignificant toxicities such as alopecia).
T2	Context_Error 157 209	Subjects receiving any other investigational agents.
T3	Condition 232 258	tumor lysis syndrome (TLS)
T4	Condition 325 361	central nervous system (CNS) disease
T5	Condition 385 403	meningeal lymphoma
T6	Qualifier 373 384	symptomatic
T7	Condition 413 437	CNS parenchymal lymphoma
T9	Condition 458 476	allergic reactions
T10	Qualifier 451 457	severe
T12	Drug 491 557	compounds of similar chemical or biologic composition to rituximab
T11	Drug 491 547;561 592	compounds of similar chemical or biologic composition to other agents used in this study
T13	Undefined_semantics 491 592	compounds of similar chemical or biologic composition to rituximab or other agents used in this study
T15	Undefined_semantics 595 642	Subjects with uncontrolled intercurrent illness
T16	Condition 646 658	HIV-positive
T17	Procedure 671 705	combination antiretroviral therapy
T20	Parsing_Error 913 1024	Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.
T21	Not_a_criteria 913 1024	Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.
T22	Not_a_criteria 1025 1164	HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment.
T23	Measurement 1204 1227	hepatitis B virus (HBV)
T24	Measurement 1229 1264	hepatitis B surface antigen (HBsAg)
T25	Measurement 1269 1295	hepatitis C (HCV) antibody
T26	Value 1178 1186	positive
T27	Measurement 1328 1340	HCV antibody
T28	Value 1315 1323	positive
T29	Measurement 1362 1365	HCV
T30	Value 1349 1357	negative
T32	Procedure 1369 1400	polymerase chain reaction (PCR)
T33	Condition 1471 1484	HBV infection
T34	Measurement 1506 1545	total hepatitis B core antibody [HBcAb]
T35	Value 1497 1505	positive
T36	Measurement 1559 1564	HBsAg
T37	Value 1550 1558	negative
T38	Measurement 1585 1592	HBV DNA
T39	Value 1596 1608	undetectable
T41	Grammar_Error 1566 1581	may be included
T42	Non-query-able 1610 1672	These patients must be willing to undergo monthly DNA testing.
T43	Person 1674 1679	Women
T44	Condition 1688 1696	pregnant
T45	Condition 1700 1709	lactating
T46	Condition 1711 1733	Malabsorption syndrome
T47	Condition 1743 1799	condition that precludes enteral route of administration
T48	Undefined_semantics 1743 1799	condition that precludes enteral route of administration
T49	Drug 1801 1813	Chemotherapy
T50	Procedure 1817 1826	radiation
T51	Temporal 1827 1880	within 3 weeks of the first scheduled study treatment
T52	Reference_point 1845 1880	the first scheduled study treatment
T53	Temporal 1883 1899	Less than 2-year
T54	Condition 1900 1912	disease free
T55	Condition 1926 1944	primary malignancy
T56	Qualifier 1918 1925	another
T57	Condition 1957 2001	squamous or basal cell carcinoma of the skin
T58	Condition 2003 2036	"in-situ" carcinoma of the cervix
T59	Condition 2003 2036;2040 2046	"in-situ" carcinoma of the cervix breast
T60	Condition 2048 2077	superficial bladder carcinoma
T61	Condition 2101 2126	localized prostate cancer
T62	Measurement 2139 2177	prostate specific antigen (PSA) levels
T63	Value 2132 2138	normal
T65	Procedure 2216 2237	anti-cancer treatment
T66	Condition 2250 2268	primary malignancy
T67	Qualifier 2242 2249	another
T68	Temporal 2269 2292	more than 2 years prior
T69	Reference_point 2296 2305	screening
T70	Negation 2306 2318	are eligible
T71	Procedure 2436 2449	Major surgery
T72	Procedure 2462 2480	diagnostic surgery
T73	Temporal 2482 2496	within 2 weeks
T74	Drug 2552 2576	systemic corticosteroids
T75	Drug 2593 2603	prednisone
T76	Multiplier 2604 2625	higher than 10 mg/day
T77	Multiplier 2542 2551	high dose
T78	Condition 2499 2516	Medical condition
T79	Undefined_semantics 2499 2516	Medical condition
T80	Temporal 2527 2534	chronic
T82	Temporal 2649 2657	<15 days
T83	Drug 2674 2689	glucocorticoids
T84	Drug 2691 2701	prednisone
T85	Multiplier 2702 2708;2718 2723	100 mg daily
T86	Grammar_Error 2740 2753	is acceptable
T87	Drug 2778 2805	xanthine oxidase inhibitors
T88	Drug 2810 2821	rasburicase
T89	Condition 2762 2769	allergy
T90	Condition 2762 2769	allergy
T91	Drug 2831 2839	warfarin
T92	Procedure 2855 2870	Anticoagulation
T93	Drug 2876 2904	low-molecular weight heparin
T94	Drug 2911 2921	enoxaparin
T95	Drug 2926 2952	direct thrombin inhibitors
T96	Grammar_Error 2953 2966	is permitted.
T97	Temporal 3027 3039	7 days prior
T98	Reference_point 3047 3071	first dose of study drug
T99	Drug 3083 3093	venetoclax
T100	Procedure 3083 3108	venetoclax administration
T101	Drug 3110 3134	Strong CYP3A4 inhibitors
T102	Drug 3164 3175	fluconazole
T103	Drug 3177 3189	ketoconazole
T104	Drug 3195 3209	clarithromycin
T105	Drug 3213 3235	strong CYP3A4 inducers
T106	Drug 3264 3272	rifampin
T107	Drug 3274 3287	carbamazepine
T112	Drug 3301 3320	live-virus vaccines
T113	Temporal 3321 3341	within 28 days prior
T114	Reference_point 3345 3378	the initiation of study treatment
T115	Non-query-able 3382 3390	need for
T116	Drug 3391 3410	live-virus vaccines
T117	Temporal 3414 3429	any time during
T118	Reference_point 3430 3445	study treatment
T119	Observation 3382 3390	need for
T120	Undefined_semantics 3448 3588	Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary.
T121	Context_Error 3448 3588	Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary.
T122	Drug 3599 3618	Weak CYP3A inducers
T123	Drug 3590 3598;3604 3618	Moderate CYP3A inducers
T124	Drug 3627 3636	efavirenz
T125	Drug 3641 3654	oxcarbazepine
T128	Drug 3656 3673	CYP2C8 substrates
T129	Undefined_semantics 3656 3673	CYP2C8 substrates
T130	Drug 3682 3700	thiazolidinediones
T131	Drug 3702 3712	glitazones
T132	Drug 3725 3732	statins
T133	Qualifier 3718 3724	select
T134	Drug 3820 3837	CYP2C9 substrates
T135	Drug 3846 3857	tolbutamide
T136	Drug 3973 3990	CYP2C9 substrates
T137	Drug 4031 4040	phenytoin
T138	Qualifier 3998 4022	narrow therapeutic index
T139	Subjective_judgement 3944 4040	It is recommended to exclude CYP2C9 substrates with a narrow therapeutic index such as phenytoin
T18	Non-representable 796 912	In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy.
T19	Negation 2451 2461	other than
T140	Negation 1946 1956	other than
